Elston responds on AI evidence synthesis and transparency

By Daniel Okafor

Volume 95, Issue 5 of the Journal of the American Academy of Dermatology, dated November 2026, carries Dirk M. Elston’s response to Kahn et al. on artificial intelligence in evidence synthesis. Kahn et al.’s paper is titled “Artificial intelligence in evidence synthesis: Benefits, limitations, and the importance of transparent reporting.”

The supplied citation names Elston as the sole listed author.

What does the publication establish?

The title identifies Elston’s item as a response rather than a report of a clinical cohort or trial.

The record names no skin condition, patient group, study design, intervention, comparator, endpoint, sample size, effect estimate, confidence interval, or recommendation.

Because the citation names no patients, comparator, endpoint, or analysis, it cannot establish safety, efficacy, or performance for any dermatologic intervention or diagnostic workflow change.

For now, this is a publication event, not a clinical result.

What does the title say about AI?

The key wording is exact: “Benefits, limitations, and the importance of transparent reporting.”

That wording places claimed strengths and shortcomings within one frame while making reporting the condition for scrutiny.

The record gives no abstract, methods, results, tables, or explanatory text from Kahn et al. or Elston.

Readers cannot determine which applications or performance measures the papers considered, including speed, accuracy, consistency, workload, bias, or reproducibility.

The title identifies transparency as a central issue, not a proven clinical benefit.

What clinical findings can readers use?

No clinical finding can be assigned to this publication from the information supplied.

The record includes no baseline or follow-up values for PASI, EASI, Breslow thickness, AJCC stage, lesion counts, recurrence, survival, or quality of life, so no patient-level or group-level effect can be calculated.

There is no denominator to convert into patients, procedures, or years of follow-up.

No claim about psoriasis, eczema, acne, or skin-cancer detection, treatment, survival, or recurrence can follow from this citation.

The takeaway is simple: no clinical claim travels beyond this record.

Where does Elston’s position stand?

Only the subject matter and framing can be reported from the citation.

Because neither the response nor the underlying paper appears in abstract or excerpt form here, the citation cannot establish whether Elston accepts Kahn’s conclusions, rejects them, or narrows them to specific uses.

The title also leaves the meaning of transparent reporting unspecified.

No methods standard, checklist, reporting guideline, or proposed workflow appears in the supplied material.

Elston’s substantive position remains undocumented in this record.

What can readers quote accurately?

The source contains no quotation from Elston, Kahn, or a JAAD editor.

The only exact language available for attribution comes from the titles, rather than from a person, which means any attempt to present Elston as endorsing a sentence would exceed the documented source.

Two phrases can be quoted accurately: the article type, “Response to Kahn et al.,” and Kahn’s framing, “Benefits, limitations, and the importance of transparent reporting.”

Neither phrase represents an attributable spoken or written statement beyond its appearance in a title.

Readers should quote the titles and avoid putting words in Elston’s mouth.

What changes for dermatology practice?

Dermatology practices receive no coding code, reimbursement rate, coverage decision, device parameter, injectable formulation, staffing recommendation, or implementation timetable from this publication record documented here.

There is no basis to change a treatment algorithm, alter lesion screening, or revise institutional policy from this citation.

Any adoption of AI in evidence workflows would require methods and reporting details beyond the metadata supplied.

Practice should not change on this citation alone.

What evidence comes next?

To assess the response’s significance, readers need the full text and Kahn et al.’s underlying article.

The next useful evidence will come from those complete documents, including their methods, cited evidence, proposed reporting standards, and any limits they explicitly acknowledge.

The full article should also state its article type, scope, central argument, and any recommendations.

Until then, the publication establishes authorship, date, venue, and subject, but not clinical efficacy.

The full text is the next necessary evidence.